{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:10:34Z","timestamp":1790683834669,"version":"4.1.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A 68-year-old White man presented with a 3-month history of two nontender, pruritic, erythematous plaques on his left arm. He had a medical history of chronic plaque psoriasis that has been stable on guselkumab treatment, an anti-interleukin-23 monoclonal antibody, for 5 years. The lesions persisted, despite topical treatments. His medical history also included previous cutaneous squamous cell carcinoma, recurrent penile Bowen disease and psoriasis that responded inadequately to \u00admultiple biologics before the initiation of guselkumab. A biopsy of a persistent lesion was carried out, which confirmed the diagnosis of cutaneous leishmaniasis. Histopathology demonstrated extensive alignment of amastigotes along the peripheries of histocytes, a pathognomonic sign known as the \u2018marquee sign\u2019. Physical examinations and serology were unremarkable. Polymerase chain reaction of the tissue biopsy identified possible involvement of Leishmania donovani and Leishmania mexicana. Unremarkable computed tomography of the thorax, abdomen and pelvis, and a negative rapid antigen K39 test eliminated the likelihood of visceral involvement. Discussion at a leishmaniasis multidisciplinary team meeting resulted in a final diagnosis of L. donovani cutaneous leishmaniasis. The patient recovered well after completing a 4-week course of oral miltefosine. Cases of leishmaniasis associated with the use of biologics associated have so far arisen mainly from tumour necrosis factor-\u03b1 inhibitors. To our knowledge, this is the first documented case of cutaneous leishmaniasis in a patient treated with guselkumab. Our case emphasizes the importance of considering potential parasitic infections when faced with persistent lesions in patients who are immunosuppressed, especially those receiving biologic therapy.<\/jats:p>","DOI":"10.1093\/skinhd\/vzag080","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:23:58Z","timestamp":1777638238000},"page":"605-608","source":"Crossref","is-referenced-by-count":1,"title":["A new association of cutaneous leishmaniasis with guselkumab in a patient with chronic psoriasis"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3522-9553","authenticated-orcid":false,"given":"Yi-Hsuan","family":"Chiang","sequence":"first","affiliation":[{"name":"Dermatology Department, University Hospital of Wales , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5227-3890","authenticated-orcid":false,"given":"Sarah","family":"Winter","sequence":"additional","affiliation":[{"name":"Dermatology Department, University Hospital of Wales , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunatha","family":"Kalavala","sequence":"additional","affiliation":[{"name":"Dermatology Department, University Hospital of Wales , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026073105085485200_vzag080-B1","author":"World Health Organization"},{"key":"2026073105085485200_vzag080-B2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.12688\/f1000research.11120.1","article-title":"Leishmaniasis: a review","volume":"6","author":"Torres-Guerrero","year":"2017","journal-title":"F1000Res"},{"key":"2026073105085485200_vzag080-B3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.apjtm.2016.06.021","article-title":"Worldwide risk factors in leishmaniasis","volume":"9","author":"Oryan","year":"2016","journal-title":"Asian Pac J Trop Med"},{"key":"2026073105085485200_vzag080-B4","author":"Abbott"},{"key":"2026073105085485200_vzag080-B5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/tropicalmed8120507","article-title":"Cutaneous leishmaniasis prevalence and clinical overview: a single center study from Saudi Arabia, Eastern Region, Al-Ahsa","volume":"8","author":"Al-Dhafiri","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"2026073105085485200_vzag080-B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvoice.2024.04.006","article-title":"Laryngeal leishmaniasis: a neglected, emerging disease in Northern Italy","author":"Lazzeroni","year":"2024","journal-title":"J Voice"},{"key":"2026073105085485200_vzag080-B7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.16-84256","article-title":"Diagnosis and treatment of leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)","volume":"96","author":"Aronson","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"2026073105085485200_vzag080-B8","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/pathogens12070969","article-title":"From infection to death: an overview of the pathogenesis of visceral leishmaniasis","volume":"12","author":"Costa","year":"2023","journal-title":"Pathogens"},{"key":"2026073105085485200_vzag080-B9","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101700","article-title":"Relapsing cutaneous leishmaniasis in a patient requiring TNF-\u03b1-inhibitor infliximab for Takayasu-arteritis: case report and review of the literature","volume":"37","author":"Heinemann","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"2026073105085485200_vzag080-B10","article-title":"Let off the leash: kala-azar following the use of tumour necrosis factor antibodies","volume":"2010","author":"Khan","year":"2010","journal-title":"Case Rep"},{"key":"2026073105085485200_vzag080-B11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jdcr.2017.09.020","article-title":"Plurifocal cutaneous leishmaniasis during treatment with ustekinumab","volume":"4","author":"Rakotonarivo","year":"2018","journal-title":"JAAD Case Rep"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/605\/68518977\/vzag080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/605\/68518977\/vzag080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:08:57Z","timestamp":1785488937000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/4\/605\/8707118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":11,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,6,12]]},"published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag080","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,12]]}}}